US 11,952,344 B2
Heterocyclic compound and use thereof
Yuya Oguro, Fujisawa (JP); Makoto Kamata, Fujisawa (JP); Shuhei Ikeda, Fujisawa (JP); Takeshi Wakabayashi, Fujisawa (JP); Norihito Tokunaga, Fujisawa (JP); Taku Kamei, Fujisawa (JP); Mitsuhiro Ito, Fujisawa (JP); Shigemitsu Matsumoto, Fujisawa (JP); Hirotaka Kamitani, Fujisawa (JP); Takaharu Hirayama, Fujisawa (JP); Toshio Tanaka, Fujisawa (JP); Hiroshi Banno, Fujisawa (JP); Nobuyuki Takakura, Fujisawa (JP); Jinichi Yonemori, Fujisawa (JP); and Takuya Fujimoto, Fujisawa (JP)
Assigned to Takeda Pharmaceutical Company Limited, Osaka (JP)
Appl. No. 17/754,118
Filed by TAKEDA PHARMACEUTICAL COMPANY LIMITED, Osaka (JP)
PCT Filed Sep. 25, 2020, PCT No. PCT/IB2020/000772
§ 371(c)(1), (2) Date Mar. 24, 2022,
PCT Pub. No. WO2021/059017, PCT Pub. Date Apr. 1, 2021.
Claims priority of application No. 2019-174311 (JP), filed on Sep. 25, 2019.
Prior Publication US 2022/0340527 A1, Oct. 27, 2022
Int. Cl. C07D 213/61 (2006.01); A61K 31/444 (2006.01); A61K 31/495 (2006.01); A61P 25/00 (2006.01); A61P 29/00 (2006.01); C07D 211/04 (2006.01); C07D 213/65 (2006.01); C07D 213/68 (2006.01); C07D 221/04 (2006.01); C07D 237/08 (2006.01); C07D 239/26 (2006.01); C07D 239/34 (2006.01); C07D 333/38 (2006.01); C07D 401/12 (2006.01); C07D 405/02 (2006.01)
CPC C07D 211/04 (2013.01) [C07D 237/08 (2013.01); C07D 239/26 (2013.01); C07D 405/02 (2013.01)] 5 Claims
 
1. A compound represented by the formula (I):

OG Complex Work Unit Chemistry
wherein
R1 is

OG Complex Work Unit Chemistry
wherein
X is CH or a nitrogen atom;
Ra is
(1) a C1-3 alkyl group optionally substituted by fluorine atom(s),
(2) a C3-6 cycloalkyl group optionally substituted by fluorine atom(s),
(3) a C1-6 alkoxy group optionally substituted by fluorine atom(s), or
(4) a C3-6 cycloalkyloxy group optionally substituted by fluorine atom(s);
Rb is
(1) a hydrogen atom,
(2) a C1-6 alkyl group optionally substituted by fluorine atom(s),
(3) a C1-6 alkoxy group optionally substituted by fluorine atom(s), or
(4) a halogen atom; and
Rc is
(1) a C2-6 alkyl group optionally substituted by fluorine atom(s),
(2) a C1-6 alkoxy group optionally substituted by fluorine atom(s), or
(3) a halogen atom; and
R2 is
(1)

OG Complex Work Unit Chemistry
wherein
Rd is
(a) a C3-6 cycloalkyl group optionally substituted by fluorine atom(s),
(b) a C1-6 alkoxy group optionally substituted by fluorine atom(s),
(c) a C3-6 cycloalkyloxy group optionally substituted by fluorine atom(s),
(d) a difluoromethyl group, or
(e) a trifluoromethyl group; and
Rf1 and Rf2 are each independently a hydrogen atom, a fluorine atom, a chlorine atom, or a methyl group,
(2)

OG Complex Work Unit Chemistry
wherein
Re is
(a) a C3-6 cycloalkyl group optionally substituted by fluorine atom(s),
(b) a C1-6 alkoxy group optionally substituted by fluorine atom(s),
(c) a C3-6 cycloalkyloxy group optionally substituted by fluorine atom(s), or
(d) a C1-2 alkyl group substituted by fluorine atom(s); and
ring B is optionally further substituted by 1 to 3 substituents selected from a fluorine atom, a chlorine atom, and a methyl group, or
(3)

OG Complex Work Unit Chemistry
wherein
ring C is further substituted by 1 or 2 substituents selected from
(a) a C3-6 cycloalkyl group optionally substituted by fluorine atom(s),
(b) a C1-6 alkoxy group optionally substituted by fluorine atom(s),
(c) a C3-6 cycloalkyloxy group optionally substituted by fluorine atom(s), and
(d) a C1-2 alkyl group substituted by fluorine atom(s),
or a pharmacologically acceptable salt thereof.